Loading…
Loading…
Chronic myeloid leukemia is a myeloproliferative cancer driven by the BCR-ABL1 fusion gene and treated with tyrosine kinase inhibitors.
Quick Answer
Chronic myeloid leukemia is a myeloproliferative cancer driven by the BCR-ABL1 fusion gene and treated with tyrosine kinase inhibitors. Dr. Sachita Baniya (NMC 20158, 8+ years of clinical experience in haematology and haemato-oncology) evaluates chronic myeloid leukemia (cml) at Kathmandu Neurology Clinic & Cognitive Center, 117 Lal Durbar Marg, Kathmandu, Bagmati Province 44600, Nepal — evidence-based, medically reviewed.
CML is characterised by the Philadelphia chromosome, which creates the BCR-ABL1 fusion. It usually presents in chronic phase with leukocytosis and splenomegaly. Tyrosine kinase inhibitors have transformed the disease into a long-term condition for most patients, monitored by quantitative BCR-ABL1 testing.
Diagnosis is confirmed by cytogenetics showing t(9;22) or molecular detection of BCR-ABL1. Blood counts, spleen assessment, risk score and baseline organ function are recorded before starting a tyrosine kinase inhibitor.
Tyrosine kinase inhibitors are the main treatment. Response is monitored with quantitative BCR-ABL1 at defined milestones, and therapy is adjusted for intolerance, resistance or loss of response. Treatment-free remission is considered only in selected patients under strict monitoring.
Management is individualized and discussed with benefits, limitations, and follow-up.
There is no proven prevention. Avoiding unnecessary radiation exposure is reasonable general advice.
Red flags — seek urgent care
CML is usually controlled long term with tyrosine kinase inhibitors rather than cured in the traditional sense. Some patients achieve sustained deep molecular responses and may be considered for treatment-free remission under close supervision.
Monitoring is usually performed at 3, 6 and 12 months after starting therapy, then periodically once a stable response is achieved. The exact schedule depends on the response and any treatment changes.
The team reviews adherence, drug interactions, tolerability and BCR-ABL1 trends, and may test for kinase domain mutations. A different TKI or other treatment may be recommended.
Yes, untreated or resistant CML can progress to blast phase, which behaves like acute leukemia. Regular monitoring and prompt response to changing results are important.
Only within a supervised treatment-free remission programme, after sustained deep molecular response and with frequent monitoring. Stopping without supervision risks relapse.
Pregnancy requires specialist planning because some TKIs carry fetal risk. Contraception and pregnancy intention should be discussed before and during treatment.
Report fluid retention, breathlessness, rash, diarrhoea, muscle cramps, liver problems or unusual bleeding. Most side effects can be managed with dose adjustment or a switch in therapy.
Bone marrow examination is often performed at diagnosis but is not routinely repeated when molecular monitoring is adequate. It is used if progression or another marrow disorder is suspected.
Specialist assessment for abnormal blood counts, anaemia, low platelets, bleeding, clotting and suspected blood disorders.
Diagnosis, risk stratification and treatment planning for acute and chronic leukemias.
Cytogenetics, FISH, PCR and next-generation sequencing for blood cancers.
Chronic lymphocytic leukemia is an indolent cancer of mature B lymphocytes that often needs monitoring rather than immediate treatment.
Myeloproliferative neoplasms are clonal marrow disorders with overproduction of blood cells and a risk of thrombosis and progression.
Primary myelofibrosis is a myeloproliferative neoplasm with marrow fibrosis, splenomegaly and progressive cytopenias.
Haematology
CML and TKI Therapy: Why BCR-ABL1 Monitoring Matters
Chronic myeloid leukemia is controlled with tyrosine kinase inhibitors. Regular BCR-ABL1 monitoring tells you whether treatment is working.
Haematology
Measurable Residual Disease: Why 'No Blasts Seen' Is Not Always Remission
MRD testing can detect cancer cells below the limit of microscopy. Learn how it guides treatment in leukemia and myeloma.
Content on this website is for general educational purposes only and does not constitute medical advice, diagnosis, or treatment. It is not a substitute for evaluation by a qualified healthcare professional. Always seek the advice of your physician or other qualified provider with any questions regarding a medical condition. Never disregard professional medical advice or delay seeking it because of something you have read on this website. In case of a medical emergency, contact emergency services immediately. No doctor–patient relationship is established by use of this site or by contacting the clinic through the site.
Reviewed by Dr. Jitendra Prasad Yadav • Last reviewed: 2026-11-10
Content is educational and aligns with standard medical references; individual evaluation may vary. External links provide context and do not imply endorsement.
Doctor — medically reviewed
Dr. Sachita Baniya
Consultant Haemato-Oncologist & Clinical Hematologist • MBBS, FCPS (Clinical Haematology) • NMC 20158
This condition guide was medically reviewed by Dr. Sachita Baniya.
On this site
Article information
Emergency
For sudden neurologic change, thunderclap headache, or seizure >5 min, seek emergency services now.